New treatment eliminates bladder cancer in 82% of patients
11 days ago
- #bladder-cancer
- #drug-delivery
- #clinical-trial
- New drug-releasing system, TAR-200, eliminated tumors in 82% of patients with high-risk non-muscle-invasive bladder cancer in a phase 2 clinical trial.
- TAR-200 slowly releases gemcitabine into the bladder over three weeks per treatment cycle, proving more effective than traditional liquid solutions.
- The clinical trial, SunRISe-1, involved 85 patients globally, with 70 patients seeing their cancer disappear after treatment.
- TAR-200 was well-tolerated with minimal side effects, unlike combination therapy with another immunotherapy drug, which was less effective and had more side effects.
- The U.S. FDA has granted TAR-200 a New Drug Application Priority Review, indicating quicker action on its approval.
- Johnson & Johnson manufactures TAR-200, and further research is ongoing to explore slow-release cancer drugs.